A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
Gila Therapeutics, Inc. · Obesity & Overweight
Phase 4
Recruiting
40
2026-07
Industry sponsor intelligence
Gila Therapeutics, Inc.Clinical Pipeline.
Lead-sponsor view of Gila Therapeutics, Inc.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 1
- Active
- 0
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 40
Pipeline overview
Programs by phase and activity.
Velocity
Gila Therapeutics, Inc. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 20
Phase 30
Phase 41
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Semaglutide → | 1 | 0 | 0 | 0 | 1 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All Gila Therapeutics, Inc. studies.
This page groups studies where Gila Therapeutics, Inc. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates